Laboratory Characteristics in Chronic Atrophic Acrodermatitis

Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02147262

Enrollment

Registered

2014-05-26

Start date

2013-07-31

Completion date

2020-07-31

Last updated

2018-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atrophic Acrodermatitis

Keywords

chronic atrophic acrodermatitis, Lyme borreliosis, molecular characteristics, outcome

Brief summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu lato.

Interventions

DRUGdoxycycline orally, 100 mg, bid, 14 days

DRUGdoxycycline orally, 100 mg, bid, 28 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* chronic atrophic dermatitis in patients \>18 years

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
inflammatory proteins in patients with chronic atrophic dermatitis	up to 24 months	The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses.

Secondary

Measure	Time frame
clinical characteristics of patients with chronic atrophic dermatitis treated with doxycycline for 14 or 28 days	at enrollment, at 2, 6 12 and 24 months follow-up

Other

Measure	Time frame	Description
gene polymorphisms in patients with chronic atrophic dermatitis	at enrollment, at 6 months follow-up	The expression of disease-relevant genomic variants will be assessed using ImmunoChip.
transcriptome profiles in patients with chronic atrophic dermatitis	at enrollment	We will use RNA sequencing of individual immune cell subtypes from patients to determine their transcriptome.

Countries

Slovenia

Contacts

Primary ContactDasa Stupica, MD, PhD

cerar.dasa@gmail.com+386 1 522 2110

Backup ContactFranc Strle, MD, PhD

franc.strle@kclj.si+386 1 522 2610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026